Should FDA restructure its drug review process

Flickr user Auntie P/Creative Commons

Pills.

Article Highlights

  • #FDA efforts to resolve scientific differences are causing it to miss review goals that it commits to as part of the #PDUFA @ScottGottliebMD

    Tweet This

  • Managers leave it to FDA’s external advisors to resolve disputes, rather than work to reach an internal consensus through the agency’s scientific process @ScottGottliebMD

    Tweet This

  • Complex scientific views are the product of agreement formed among experts with diverse training, who hail from different disciplines and backgrounds @ScottGottliebMD

    Tweet This

In recent years, the Food and Drug Administration (FDA) has struggled with an increasing number of disagreements among its scientific staff. Many of these disputes have spilled out into public view. There seems to be less unity around hard decisions and more instances where FDA staff labor to collaborate and work toward a consensus opinion. A growing number of these disagreements are being brought before FDA’s public advisory committees for mediation. The agency’s efforts to resolve scientific differences and to take final actions are causing it to miss review goals that it commits to as part of the Prescription Drug User Fee Act (PDUFA).

"When experts from these different silos disagree, there is a waning expectation that they should sort through their differing interpretations of data to reach a scientific accord." -- Scott Gottlie

To some degree, these events are a product of the broader political environment in which FDA must operate. Congressional and media scrutiny celebrates the notion of a lone “whistle-blower” tilting against the prevailing orthodoxy. This can feed an internal culture that encourages individuals to cling to dissenting opinions, even when those views are rejected by more senior FDA scientists. The political culture spooks managers away from challenging scientists who cling to outlying conclusions, even in cases where those opinions are based on flawed analysis.

The increasing preference has been to sidestep these internal disputes by bringing them before the agency’s public advisory committee meetings. The resulting transparency insulates managers from charges that they “suppressed” dissenting views or intervened to guide the decision to a particular outcome. Managers leave it to FDA’s external advisors to sort out these disputes, rather than work to reach a definitive, internal consensus through the agency’s scientific process.

While this practice may be politically expedient it is an inefficient way to run a scientific enterprise. It also reduces FDA’s ability to leverage the collective wisdom of its scientific personnel. Complex scientific views are the product of agreement formed among experts with diverse training, who hail from different disciplines and backgrounds. But at FDA, experts from different scientific disciplines work in silos. When experts from these different silos disagree, there is a waning expectation that they should sort through their differing interpretations of data to reach a scientific accord. The disagreements are too easily “turfed” to advisory committees to be resolved. While the political culture is pressuring the agency toward these ends, the agency’s organizational structure may also be contributing to a lack of collaboration by discouraging opportunities for collaboration inside the drug review process.

Scott Gottlieb, M.D., is a resident fellow at AEI.

Also Visit
AEIdeas Blog The American Magazine
About the Author

 

Scott
Gottlieb
  • Scott Gottlieb, M.D., a practicing physician, has served in various capacities at the Food and Drug Administration, including senior adviser for medical technology; director of medical policy development; and, most recently, deputy commissioner for medical and scientific affairs. Dr. Gottlieb has also served as a senior policy adviser at the Centers for Medicare & Medicaid Services. 

    Click here to read Scott’s Medical Innovation blog.


    Follow Scott Gottlieb on Twitter.

  • Phone: 202.862.5885
    Email: scott.gottlieb@aei.org
  • Assistant Info

    Name: Kelly Funderburk
    Phone: 202.862.5920
    Email: Kelly.Funderburk@AEI.org

What's new on AEI

image Recovering from tax time blues
image 10 welfare reform lessons
image Let HHS nominee Sylvia Burwell explain Obamacare lie
image Why bold ideas backfire in politics
AEI on Facebook
Events Calendar
  • 14
    MON
  • 15
    TUE
  • 16
    WED
  • 17
    THU
  • 18
    FRI
Wednesday, April 16, 2014 | 10:00 a.m. – 11:00 a.m.
Calling treason by its name: A conversation with Liam Fox

Join us at AEI as the Right Honorable Liam Fox sits down with Marc Thiessen to discuss and debate whether America’s intelligence agencies have infringed on the personal privacy of US citizens.

Event Registration is Closed
Thursday, April 17, 2014 | 4:00 p.m. – 5:00 p.m.
The curmudgeon's guide to getting ahead

How can young people succeed in workplaces dominated by curmudgeons who are judging their every move? At this AEI book event, bestselling author and social scientist Charles Murray will offer indispensable advice for navigating the workplace, getting ahead, and living a fulfilling life.

No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.